Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cyclopharm Limited ( (AU:CYC) ) has issued an announcement.
Cyclopharm Limited has disclosed a change in director James McBrayer’s holdings, with the executive acquiring 10,526 additional ordinary shares on 12 March 2026 through participation in a share purchase plan. The transaction, valued at $9,999.70, lifts McBrayer’s total direct and associated holdings to 5,320,106 shares, signaling continued insider support for the company’s equity and providing transparency to investors regarding board-level ownership changes.
The most recent analyst rating on (AU:CYC) stock is a Hold with a A$0.69 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
More about Cyclopharm Limited
Cyclopharm Limited is an Australian-listed company operating in the healthcare and medical sector. The company is involved in activities related to listed securities and capital markets, with its shares traded on the ASX and directors holding interests through personal and associated investment entities.
Average Trading Volume: 89,869
Technical Sentiment Signal: Sell
Current Market Cap: A$88.05M
Learn more about CYC stock on TipRanks’ Stock Analysis page.